{"id":108344,"date":"2024-05-15T16:59:28","date_gmt":"2024-05-15T16:59:28","guid":{"rendered":"https:\/\/www.atlasrleye.com\/?page_id=108344"},"modified":"2025-03-13T10:26:13","modified_gmt":"2025-03-13T10:26:13","slug":"clinical-case-12","status":"publish","type":"page","link":"https:\/\/www.atlasrleye.com\/en\/proliferative-diabetic-retinopathy-in-type-1-diabetes\/clinical-case-12\/","title":{"rendered":"Clinical Case 12"},"content":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=”DIABETIC RETINOPATHY” font_container=”tag:h5|font_size:22px|text_align:center|color:%23000000″ use_theme_fonts=”yes” link=”url:https%3A%2F%2Fwww.atlasrleye.com%2Fretinopatia-diabetica%2F|title:Diabetic%20Retinopathy|”][vc_text_separator title=”” i_icon_fontawesome=”fas fa-eye” i_color=”custom” i_size=”lg” color=”custom” border_width=”8″ css=”.vc_custom_1637080776101{margin-bottom: -5px !important;}” add_icon=”true” accent_color=”#bababa” i_custom_color=”#bababa”][vc_custom_heading text=”Proliferative Diabetic Retinopathy in Type 1 Diabetes – Clinical Case 12″ font_container=”tag:h1|text_align:center|color:%235f1b52″ use_theme_fonts=”yes” css=”” link=”url:https%3A%2F%2Fwww.atlasrleye.com%2Fen%2Fproliferative-diabetic-retinopathy-in-type-1-diabetes%2F|title:PROLIFERATIVE%20DIABETIC%20RETINOPATHY%20IN%20TYPE%201%20DIABETES|”]

<\/div>[\/vc_column][\/vc_row][vc_row][vc_column]
<\/div>
<\/div>[\/vc_column][\/vc_row][vc_row gap=”35″ equal_height=”yes”][vc_column width=”1\/2″][vc_row_inner][vc_column_inner width=”1\/2″][vc_single_image image=”108358″ img_size=”medium” alignment=”center” onclick=”link_image” css=””][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

Fluorescein angiogram in a 55-year-old patient diagnosed with diabetes more than 20 years ago, showing microaneurysms and areas of ischemia. <\/span><\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][vc_column width=”1\/2″][vc_row_inner][vc_column_inner width=”1\/2″][vc_single_image image=”108309″ img_size=”medium” alignment=”center” onclick=”link_image” css=””][vc_single_image image=”108362″ img_size=”medium” alignment=”center” onclick=”link_image” css=””][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

Eight months after cataract surgery (phacoemulsification and IOL), vitrectomy and laser photocoagulation (neovascular glaucoma). Treatment with intraocular injections of anti-VEGFs.<\/span><\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n

Evaluations
\n<\/span><\/h3>\n

[\/vc_column_text][vc_tta_accordion active_section=”99″ no_fill=”true” collapsible_all=”true”][vc_tta_section i_icon_fontawesome=”far fa-calendar-alt” add_icon=”true” title=”1st Evaluation – 14 02 2023″ tab_id=”1671795919289-748acc60-ba6d”][vc_row_inner][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

\n
\n

Autofluorescence<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108053,108057″ img_size=”193*206″ css=””][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

\n
\n

Infrared<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108004,108008″ img_size=”193*206″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”1\/3″][vc_column_text css=””]<\/p>\n

\n
\n

RNFL \u2013 Thickness Image<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108021,108025″ img_size=”160*206″ css=””][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_column_text css=””]<\/p>\n

\n
\n

Anterior Segment OCT<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108012,108017″ img_size=”300*206″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Anterior Segment Photo<\/p>\n

\n

Cataract RLE. BCVA: 20\/32 RE; 20\/20 LE.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108029,108033,108037,108041″ img_size=”300×206″ css=”.vc_custom_1718621331568{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text]<\/p>\n

\n
\n

OCT (B-Scan) longitudinal<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108069,107975,107980,107984,107988,107992,107996,108000″ img_size=”307×110″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Colour retinography<\/p>\n

\n

Diabetic retinopathy RLE. HbA1c=8,1%.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108045,108049,108061,108065″ img_size=”280×206″ css=”.vc_custom_1718616845969{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section i_icon_fontawesome=”far fa-calendar-alt” add_icon=”true” title=”2nd Evaluation – 26 06 2023″ tab_id=”1718621374193-da8b9933-ca52″][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Fluorescein Angiography<\/p>\n

\n

Iris neovascularization. Marked ischemia of the retina (RLE). Microaneurysms.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108187,108191,108195,108199,108203″ img_size=”193*206″ css=”.vc_custom_1718626917098{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”1\/3″][vc_column_text css=””]<\/p>\n

\n
\n

Autofluorescence<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108179,108183″ img_size=”183*206″ css=””][\/vc_column_inner][vc_column_inner width=”1\/3″][vc_column_text css=””]<\/p>\n

\n
\n

Infrared<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108133,108137″ img_size=”183*206″ css=””][\/vc_column_inner][vc_column_inner width=”1\/3″][vc_column_text css=””]<\/p>\n

\n
\n

Red-free<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108215,108129″ img_size=”183*206″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Anterior Segment Photo<\/p>\n

\n

BCVA: 8\/10 RE; 10\/10 LE. Minimal neovascularization on the iris border (RLE).<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108158,108162,108504,108166″ img_size=”300×206″ css=”.vc_custom_1718621676340{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text]<\/p>\n

\n
\n

OCT (B-Scan) longitudinal<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108142,108146,108150,108154″ img_size=”307×110″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Colour retinography<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108170,108174,108207,108211″ img_size=”280×206″ css=””][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section i_icon_fontawesome=”far fa-calendar-alt” add_icon=”true” title=”3rd Evaluation – postoperative – 26 07 2023″ tab_id=”1671796840330-e71e9361-6fd6″][vc_row_inner][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n

\n
\n

Autofluorescence<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108260,108264″ img_size=”193×206″ css=””][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n

\n
\n

Infrared<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108239,108243″ img_size=”193×206″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Anterior Segment Photo<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108248″ img_size=”320×206″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text]<\/p>\n

\n
\n

OCT (B-Scan) longitudinal<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108268,108272,108276,108219,108223,108227,108231,108235″ img_size=”307×110″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Colour retinography<\/p>\n

\n

LE, two weeks after cataract surgery (phacoemulsification and IOL), vitrectomy and laser photocoagulation (neovascular glaucoma). Treatment with intraocular injections of aflibercept.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108252,108256″ img_size=”251×206″ css=”.vc_custom_1718627101227{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section i_icon_fontawesome=”far fa-calendar-alt” add_icon=”true” title=”4th Evaluation – 15 03 2024″ tab_id=”1671798147691-bfbf7c13-be8d”][vc_row_inner][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n

\n
\n

Autofluorescence<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108313,108317″ img_size=”193×206″ css=””][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n

\n
\n

Infrared<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108288,108292″ img_size=”193×206″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Anterior Segment Photo<\/p>\n

\n

BCVA: 20\/25 RE; 20\/20 LE. Pseudophakia RLE.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108296,108301″ img_size=”307×260″ css=”.vc_custom_1718627407822{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text]<\/p>\n

\n
\n

OCT (B-Scan) longitudinal<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108321,108325,108280,108284″ img_size=”307×110″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Colour retinography<\/p>\n

\n

Diabetic retinopathy treated by laser photocoagulation and intraocular injections of anti-VEGFs.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”108305,108309″ img_size=”251×206″ css=”.vc_custom_1718627367506{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=”DIABETIC RETINOPATHY” font_container=”tag:h5|font_size:22px|text_align:center|color:%23000000″ use_theme_fonts=”yes” link=”url:https%3A%2F%2Fwww.atlasrleye.com%2Fretinopatia-diabetica%2F|title:Diabetic%20Retinopathy|”][vc_text_separator title=”” i_icon_fontawesome=”fas fa-eye” i_color=”custom” i_size=”lg” color=”custom” border_width=”8″ css=”.vc_custom_1637080776101{margin-bottom: -5px !important;}” add_icon=”true” accent_color=”#bababa” i_custom_color=”#bababa”][vc_custom_heading text=”Proliferative Diabetic Retinopathy in Type 1 Diabetes – Clinical Case 12″ font_container=”tag:h1|text_align:center|color:%235f1b52″ use_theme_fonts=”yes” css=”” link=”url:https%3A%2F%2Fwww.atlasrleye.com%2Fen%2Fproliferative-diabetic-retinopathy-in-type-1-diabetes%2F|title:PROLIFERATIVE%20DIABETIC%20RETINOPATHY%20IN%20TYPE%201%20DIABETES|”][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row][vc_row gap=”35″ equal_height=”yes”][vc_column width=”1\/2″][vc_row_inner][vc_column_inner width=”1\/2″][vc_single_image image=”108358″ img_size=”medium” […]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":75353,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-108344","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/108344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/comments?post=108344"}],"version-history":[{"count":12,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/108344\/revisions"}],"predecessor-version":[{"id":114910,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/108344\/revisions\/114910"}],"up":[{"embeddable":true,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/75353"}],"wp:attachment":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/media?parent=108344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}